Platelets of patients with chronic kidney disease demonstrate deficient platelet reactivity in vitro

Esther R. van Bladel, Rosa L. de Jager, Daisy Walter, Loes Cornelissen, Carlo A. Gaillard, Leonie A. Boven, Mark Roest, Rob Fijnheer*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

26 Citations (Scopus)
34 Downloads (Pure)

Abstract

Background: In patients with chronic kidney disease studies focusing on platelet function and properties often are non-conclusive whereas only few studies use functional platelet tests. In this study we evaluated a recently developed functional flow cytometry based assay for the analysis of platelet function in chronic kidney disease.

Methods: Platelet reactivity was measured using flow cytometric analysis. Platelets in whole blood were triggered with different concentrations of agonists (TRAP, ADP, CRP). Platelet activation was quantified with staining for P-selectin, measuring the mean fluorescence intensity. Area under the curve and the concentration of half-maximal response were determined.

Results: We studied 23 patients with chronic kidney disease (9 patients with cardiorenal failure and 14 patients with end stage renal disease) and 19 healthy controls. Expression of P-selectin on the platelet surface measured as mean fluorescence intensity was significantly less in chronic kidney disease patients compared to controls after maximal stimulation with TRAP (9.7 (7.9-10.8) vs. 11.4 (9.2-12.2), P = 0.032), ADP (1.6 (1.2-2.1) vs. 2.6 (1.9-3.5), P = 0.002) and CRP (9.2 (8.5-10.8) vs. 11.5 (9.5-12.9), P = 0.004). Also the area under the curve was significantly different. There was no significant difference in half-maximal response between both groups.

Conclusion: In this study we found that patients with chronic kidney disease show reduced platelet reactivity in response of ADP, TRAP and CRP compared to controls. These results contribute to our understanding of the aberrant platelet function observed in patients with chronic kidney disease and emphasize the significance of using functional whole blood platelet activation assays.

Original languageEnglish
Article number127
Number of pages6
JournalBmc nephrology
Volume13
DOIs
Publication statusPublished - 28-Sep-2012
Externally publishedYes

Keywords

  • Platelet activation
  • Haemodialysis
  • Cardiorenal syndrome
  • End-stage renal disease
  • STAGE RENAL-DISEASE
  • CHRONIC HEART-FAILURE
  • CARDIOVASCULAR-DISEASE
  • INSUFFICIENCY
  • MORTALITY
  • ERYTHROPOIETIN
  • HEMODIALYSIS
  • ASSOCIATION
  • OUTCOMES
  • DEATH

Cite this